Monday, December 23, 2024
HomeTagsExscientia

Exscientia

Exscientia acquires full rights to potential lead-in CDK7 inhibitor prior to publication of Phase 1 dose escalation data

Exscientia plc announced that it has entered into an agreement to acquire GT Apeiron's interest in its oral CDK7 inhibitor program, thereby gaining full...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics